gamma-aminobutyric acid has been researched along with Obsessive-Compulsive Disorder in 34 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Obsessive-Compulsive Disorder: An anxiety disorder characterized by recurrent, persistent obsessions or compulsions. Obsessions are the intrusive ideas, thoughts, or images that are experienced as senseless or repugnant. Compulsions are repetitive and seemingly purposeful behavior which the individual generally recognizes as senseless and from which the individual does not derive pleasure although it may provide a release from tension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We previously reported the rapid and robust clinical effects of ketamine versus saline infusions in a proof-of-concept crossover trial in unmedicated adults with obsessive-compulsive disorder (OCD)." | 9.20 | In vivo effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder: Proof of concept. ( Flood, P; Hunter, L; Kegeles, LS; Levinson, A; Mao, X; Milak, MS; Moore, H; Ogden, RT; Rodriguez, CI; Shungu, DC; Simpson, HB; Vermes, D; Xie, S, 2015) |
| "Neurodevelopmental disorders (NDDs) including autism spectrum disorder (ASD), attention-deficit hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD) are thought to arise in part from the disruption in the excitatory/inhibitory balance of gamma-aminobutyric acid (GABA) and glutamate in the brain." | 8.31 | Cerebellar gamma-aminobutyric acid: Investigation of group effects in neurodevelopmental disorders. ( Anagnostou, E; Arnold, PD; Crosbie, J; Hammill, C; Lerch, JP; Near, J; Pang, EW; Schachar, R; Taylor, MJ, 2023) |
| "We previously reported the rapid and robust clinical effects of ketamine versus saline infusions in a proof-of-concept crossover trial in unmedicated adults with obsessive-compulsive disorder (OCD)." | 5.20 | In vivo effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder: Proof of concept. ( Flood, P; Hunter, L; Kegeles, LS; Levinson, A; Mao, X; Milak, MS; Moore, H; Ogden, RT; Rodriguez, CI; Shungu, DC; Simpson, HB; Vermes, D; Xie, S, 2015) |
| "Neurodevelopmental disorders (NDDs) including autism spectrum disorder (ASD), attention-deficit hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD) are thought to arise in part from the disruption in the excitatory/inhibitory balance of gamma-aminobutyric acid (GABA) and glutamate in the brain." | 4.31 | Cerebellar gamma-aminobutyric acid: Investigation of group effects in neurodevelopmental disorders. ( Anagnostou, E; Arnold, PD; Crosbie, J; Hammill, C; Lerch, JP; Near, J; Pang, EW; Schachar, R; Taylor, MJ, 2023) |
| "A patient with Usher syndrome and psychiatric symptoms is described and the difficulties in psychiatric assessment in her case are discussed." | 1.35 | Usher syndrome and psychiatric symptoms: a challenge in psychiatric management. ( Grubic, VN; Rijavec, N, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (8.82) | 18.7374 |
| 1990's | 4 (11.76) | 18.2507 |
| 2000's | 10 (29.41) | 29.6817 |
| 2010's | 13 (38.24) | 24.3611 |
| 2020's | 4 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Pang, EW | 1 |
| Hammill, C | 1 |
| Taylor, MJ | 1 |
| Near, J | 1 |
| Schachar, R | 1 |
| Crosbie, J | 1 |
| Arnold, PD | 1 |
| Anagnostou, E | 1 |
| Lerch, JP | 1 |
| Biria, M | 1 |
| Banca, P | 1 |
| Healy, MP | 1 |
| Keser, E | 1 |
| Sawiak, SJ | 1 |
| Rodgers, CT | 1 |
| Rua, C | 1 |
| de Souza, AMFLP | 1 |
| Marzuki, AA | 1 |
| Sule, A | 1 |
| Ersche, KD | 1 |
| Robbins, TW | 1 |
| Kosová, E | 1 |
| Pajuelo, D | 1 |
| Greguš, D | 1 |
| Brunovský, M | 1 |
| Stopková, P | 1 |
| Fajnerová, I | 1 |
| Horáček, J | 1 |
| Muzyko, EA | 1 |
| Tkacheva, GA | 1 |
| Perfilova, VN | 1 |
| Matvienko, LS | 1 |
| Naumenko, LV | 1 |
| Vasil'eva, OS | 1 |
| Tyurenkov, IN | 1 |
| Winter, C | 1 |
| Greene, DM | 1 |
| Mavrogiorgou, P | 1 |
| Schaper, H | 1 |
| Sohr, R | 1 |
| Bult-Ito, A | 1 |
| Juckel, G | 1 |
| Konen, C | 1 |
| Niederst, E | 1 |
| Li, Y | 1 |
| Zhang, CC | 1 |
| Zhang, Y | 1 |
| He, N | 1 |
| Jin, H | 1 |
| Chen, W | 1 |
| Voon, V | 1 |
| Edden, RAE | 1 |
| Yan, F | 1 |
| Simpson, HB | 3 |
| Kegeles, LS | 3 |
| Hunter, L | 2 |
| Mao, X | 3 |
| Van Meter, P | 1 |
| Xu, X | 2 |
| Kimeldorf, MB | 1 |
| Pearlstein, SL | 1 |
| Slifstein, M | 2 |
| Shungu, DC | 3 |
| Denenberg, S | 1 |
| Rodriguez, CI | 1 |
| Levinson, A | 1 |
| Ogden, RT | 1 |
| Milak, MS | 1 |
| Vermes, D | 1 |
| Xie, S | 1 |
| Flood, P | 1 |
| Moore, H | 1 |
| Rolls, ET | 1 |
| Loh, M | 1 |
| Deco, G | 1 |
| Oulis, P | 2 |
| Florakis, A | 1 |
| Tzanoulinos, G | 1 |
| Papadimitriou, GN | 1 |
| Rijavec, N | 1 |
| Grubic, VN | 1 |
| Martinotti, G | 2 |
| Di Nicola, M | 2 |
| Tedeschi, D | 2 |
| Andreoli, S | 1 |
| Reina, D | 1 |
| Pomponi, M | 1 |
| Mazza, M | 1 |
| Romanelli, R | 1 |
| Moroni, N | 1 |
| De Filippis, R | 1 |
| Di Giannantonio, M | 1 |
| Pozzi, G | 2 |
| Bria, P | 1 |
| Janiri, L | 2 |
| Bhattacharyya, S | 1 |
| Khanna, S | 1 |
| Chakrabarty, K | 1 |
| Mahadevan, A | 1 |
| Christopher, R | 1 |
| Shankar, SK | 1 |
| Nikolaus, S | 1 |
| Antke, C | 1 |
| Beu, M | 1 |
| Müller, HW | 1 |
| Mourikis, I | 1 |
| Konstantakopoulos, G | 1 |
| De Vita, O | 1 |
| Monetta, M | 1 |
| Bandelow, B | 1 |
| Sher, L | 1 |
| Bunevicius, R | 1 |
| Hollander, E | 1 |
| Kasper, S | 1 |
| Zohar, J | 1 |
| Möller, HJ | 1 |
| Bender, J | 1 |
| Egashira, N | 1 |
| Abe, M | 1 |
| Shirakawa, A | 1 |
| Niki, T | 1 |
| Mishima, K | 1 |
| Iwasaki, K | 1 |
| Oishi, R | 1 |
| Fujiwara, M | 1 |
| Mataix-Cols, D | 1 |
| van den Heuvel, OA | 1 |
| Furieri, FA | 1 |
| Nakamura-Palacios, EM | 1 |
| Onder, E | 1 |
| Tural, U | 1 |
| Gökbakan, M | 1 |
| Goddard, AW | 1 |
| Shekhar, A | 1 |
| Whiteman, AF | 1 |
| McDougle, CJ | 1 |
| Petty, F | 1 |
| Davis, LL | 1 |
| Kabel, D | 1 |
| Kramer, GL | 1 |
| Corá-Locatelli, G | 2 |
| Greenberg, BD | 2 |
| Martin, JD | 1 |
| Murphy, DL | 2 |
| Martin, J | 1 |
| Chatterjee, CR | 1 |
| Ringold, AL | 1 |
| Sasaki, K | 1 |
| Sudo, T | 1 |
| Kurusu, T | 1 |
| Kiuchi, T | 1 |
| Yoshizaki, F | 1 |
| Kutin, VP | 1 |
| Kutin, GV | 1 |
| Modell, JG | 1 |
| Mountz, JM | 1 |
| Curtis, GC | 1 |
| Greden, JF | 1 |
| Hoehn-Saric, R | 1 |
| McLeod, DR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Understanding the Glutamate System in Adults With Obsessive-Compulsive Disorder With N-methyl-D Aspartate Antagonist Ketamine[NCT01100255] | Phase 2 | 15 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD[NCT02884908] | Phase 3 | 252 participants (Anticipated) | Interventional | 2016-09-30 | Active, not recruiting | ||
| Memantine for Refractory OCD Patients: a Pragmatic Double Blind, Randomized, Parallel Group, Placebo Controlled, Monocentric Trial[NCT05015595] | Phase 3 | 20 participants (Anticipated) | Interventional | 2021-09-01 | Not yet recruiting | ||
| A Prospective Randomized Controlled Open Label Trial of Symptom-triggered Benzodiazepine Versus Fixed-dose Gabapentin for Alcohol Withdrawal Syndrome[NCT03012815] | Phase 4 | 88 participants (Actual) | Interventional | 2017-02-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Patients given YBOCS (Yale Brown Obsessive-Compulsive Scale), a gold standard measure of obsessions and compulsions. For the YBOCS the minimum units are 0 and Maximum units on the total scale are 40. The higher the number on the YBOCS, the more severe the symptoms. Response was defined as at least a 35% reduction on the YBOCS. (NCT01100255)
Timeframe: 1 week
| Intervention | participants (Number) |
|---|---|
| Saline Infusion | 0 |
| Ketamine Infusion | 5 |
GAD-7 is GAD-7 is a 7-item self-administered scale of Generalized Anxiety Disorder symptoms (0 = not at all to 3 = nearly every day). Total scores range from 0 to 21. Total scores of 0-4 = minimal anxiety, Total scores of 5-9 = mild anxiety, total scores of 10-14 = moderate anxiety and total scores of 15-21 = severe anxiety. (NCT03012815)
Timeframe: Baseline and 2 days
| Intervention | score on a scale (Mean) |
|---|---|
| Gabapentin | -0.07 |
| Benzodiazepine | -3.79 |
PACS is a 5 item self-rated scale of alcohol craving (0 = none to 6 = strong urge). Total scores range from 0 (little craving for alcohol) to 30 (irresistible urge to drink alcohol) (NCT03012815)
Timeframe: Baseline and 2 days
| Intervention | score on a scale (Mean) |
|---|---|
| Gabapentin | -8.12 |
| Benzodiazepine | -8.45 |
The ESS is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in eight different activities. Most people engage in those activities at least occasionally, although not necessarily every day. The ESS score (the sum of 8 item scores, 0-3) can range from 0 to 24. The higher the ESS score, the higher that person's average sleep propensity in daily life (ASP), or their daytime sleepiness. (NCT03012815)
Timeframe: Baseline and 2 days
| Intervention | score on a scale (Mean) |
|---|---|
| Gabapentin | -0.03 |
| Benzodiazepine | 0.07 |
CIWA-Ar measures severity of 10 observed or measured alcohol withdrawal signs or symptoms. Zero to 7 points are assigned to each item, except for the last item, which is assigned 0-4 points, with a total possible score of 67. Total score ranges from 0 (best possible outcome)-67 (worst possible outcome). Lower scores (0-8) represent fewer withdrawal symptoms and less severity, scores > 8 represent more withdrawal symptoms and greater severity (NCT03012815)
Timeframe: 4 days
| Intervention | score on a scale (Mean) |
|---|---|
| Gabapentin | 13.15 |
| Benzodiazepine | 12.81 |
The length of hospital stay for Alcohol withdrawal syndrome. The time interval between admission and either discharge or the time at which Clinical Institute Withdrawal Assessment - Alcohol revised (CIWA-Ar) scores are <10 for 36 hours (up to 240 hours). Measured in hours. CIWA-Ar measures severity of 10 observed or measured alcohol withdrawal signs or symptoms. Zero to 7 points are assigned to each item, except for the last item, which is assigned 0-4 points, with a total possible score of 67. Total score ranges from 0 (best possible outcome)-67 (worst possible outcome). Lower scores (0-8) represent fewer withdrawal symptoms and less severity, scores > 8 represent more withdrawal symptoms and greater severity (NCT03012815)
Timeframe: Time to discharge or time to CIWA-Ar score < 10 for 36 hours (whichever came first) up to 240 hrs.
| Intervention | hours (Mean) |
|---|---|
| Gabapentin | 44.91 |
| Benzodiazepine | 50.50 |
The total amount of benzodiazepines administered. Measured by lorazepam equivalent, mg. (NCT03012815)
Timeframe: Time to discharge or time to CIWA-Ar score < 10 for 36 hours (whichever came first) up to 240 hrs.
| Intervention | milligrams (Mean) |
|---|---|
| Gabapentin | 5.2 |
| Benzodiazepine | 10.8 |
The number of subjects who developed seizure during their hospitalization. (NCT03012815)
Timeframe: During hospitalization (up to 240 hours).
| Intervention | Participants (Count of Participants) |
|---|---|
| Gabapentin | 0 |
| Benzodiazepine | 0 |
The number of participants experiencing delirium tremens during their hospitalization (between admission and discharge). (NCT03012815)
Timeframe: During hospitalization (up to 240 hours)
| Intervention | Participants (Count of Participants) |
|---|---|
| Gabapentin | 0 |
| Benzodiazepine | 0 |
7 reviews available for gamma-aminobutyric acid and Obsessive-Compulsive Disorder
| Article | Year |
|---|---|
[Physiopathology of obsessive-compulsive disorder--special reference to aspects of the neurochemistry].
Topics: Brain; Diagnostic Imaging; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Neurochemistry; Obsessive | 2009 |
Cortical GABA, striatal dopamine and midbrain serotonin as the key players in compulsive and anxiety disorders--results from in vivo imaging studies.
Topics: Anxiety Disorders; Cerebral Cortex; Corpus Striatum; Dopamine; gamma-Aminobutyric Acid; Humans; Mese | 2010 |
Common and distinct neural correlates of obsessive-compulsive and related disorders.
Topics: Anxiety Disorders; Frontal Lobe; gamma-Aminobutyric Acid; Humans; Limbic System; Nerve Net; Obsessiv | 2006 |
Serotoninergic mechanisms in the treatment of obsessive-compulsive disorder.
Topics: Anti-Anxiety Agents; Dopamine; Dopamine Antagonists; Excitatory Amino Acid Antagonists; gamma-Aminob | 2008 |
Serotonin dysfunction disorders: a behavioral neurochemistry perspective.
Topics: Animals; Antidepressive Agents; Anxiety Disorders; Behavior, Animal; Brain Chemistry; Cognition Diso | 1996 |
Neurophysiologic dysfunction in basal ganglia/limbic striatal and thalamocortical circuits as a pathogenetic mechanism of obsessive-compulsive disorder.
Topics: Antidepressive Agents, Tricyclic; Basal Ganglia; Corpus Striatum; Female; Functional Laterality; gam | 1989 |
Generalized anxiety disorder.
Topics: Adrenergic beta-Antagonists; Alprazolam; Animals; Anti-Anxiety Agents; Antidepressive Agents, Tricyc | 1985 |
7 trials available for gamma-aminobutyric acid and Obsessive-Compulsive Disorder
| Article | Year |
|---|---|
In vivo effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder: Proof of concept.
Topics: Adult; Cross-Over Studies; Excitatory Amino Acid Antagonists; Female; gamma-Aminobutyric Acid; Gluta | 2015 |
Pregabalin versus naltrexone in alcohol dependence: a randomised, double-blind, comparison trial.
Topics: Adult; Alcohol Withdrawal Delirium; Alcohol-Related Disorders; Anticonvulsants; Anxiety; Calcium Cha | 2010 |
Pregabalin augmentation in treatment-resistant obsessive-compulsive disorder.
Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Drug Resistance; Drug Therapy, Combination; Female | 2011 |
Pregabalin augmentation in treatment-resistant obsessive-compulsive disorder: a 16-week case series.
Topics: Adult; Anticonvulsants; Drug Resistance; Drug Therapy, Combination; Female; gamma-Aminobutyric Acid; | 2011 |
Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Alcohol Deterrents; Alcoholism; Ambulatory Care; Amines; Blood-Brain Barrie | 2007 |
Does gabapentin lead to early symptom improvement in obsessive-compulsive disorder?
Topics: Administration, Oral; Adolescent; Adult; Amines; Analysis of Variance; Anti-Anxiety Agents; Cyclohex | 2008 |
Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Administration Schedule; Drug T | 1998 |
20 other studies available for gamma-aminobutyric acid and Obsessive-Compulsive Disorder
| Article | Year |
|---|---|
Cerebellar gamma-aminobutyric acid: Investigation of group effects in neurodevelopmental disorders.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Case-Control St | 2023 |
Cortical glutamate and GABA are related to compulsive behaviour in individuals with obsessive compulsive disorder and healthy controls.
Topics: Compulsive Behavior; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Magnetic Resonance Imaging; Obs | 2023 |
Glutamatergic abnormalities in the pregenual anterior cingulate cortex in obsessive-compulsive disorder using magnetic resonance spectroscopy: A controlled study.
Topics: gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Gyrus Cinguli; Humans; Magnetic Resonance Spectro | 2023 |
Effects of Gaba Derivatives on Anxious and Compulsive Behavior in Offspring of Rats with Experimental Preeclampsia.
Topics: Animals; Animals, Outbred Strains; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Female; GABA Agon | 2020 |
Altered serotonergic and GABAergic neurotransmission in a mice model of obsessive-compulsive disorder.
Topics: Analysis of Variance; Animals; Animals, Newborn; Brain; Disease Models, Animal; Dopamine; gamma-Amin | 2018 |
Special Issue on Disease: New Advances in Psychiatry.
Topics: Animals; Brain; Cerebellum; Depression, Postpartum; Depressive Disorder; Female; gamma-Aminobutyric | 2019 |
Investigation of anterior cingulate cortex gamma-aminobutyric acid and glutamate-glutamine levels in obsessive-compulsive disorder using magnetic resonance spectroscopy.
Topics: Adult; Female; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Gyrus Cinguli; Humans; Magnetic Re | 2019 |
Assessment of glutamate in striatal subregions in obsessive-compulsive disorder with proton magnetic resonance spectroscopy.
Topics: Adolescent; Adult; Corpus Striatum; Female; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Human | 2015 |
Animal behavior case of the month. Tail chasing in a dog diagnosed as compulsive disorder.
Topics: Amines; Animals; Anticonvulsants; Behavior, Animal; Bites and Stings; Cyclohexanecarboxylic Acids; D | 2015 |
An attractor hypothesis of obsessive-compulsive disorder.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; gamma-Aminobutyric Acid; Glutamic Acid; Hu | 2008 |
Pregabalin in the treatment of benzodiazepine-induced obsessive-compulsive disorder.
Topics: Anticonvulsants; Benzodiazepines; Female; gamma-Aminobutyric Acid; Humans; Middle Aged; Obsessive-Co | 2008 |
Usher syndrome and psychiatric symptoms: a challenge in psychiatric management.
Topics: Adult; Anorexia Nervosa; Anti-Anxiety Agents; Antipsychotic Agents; Clozapine; Comorbidity; Diagnosi | 2009 |
Anti-brain autoantibodies and altered excitatory neurotransmitters in obsessive-compulsive disorder.
Topics: Adult; Aged; Autoantibodies; Basal Ganglia; Female; gamma-Aminobutyric Acid; Glutamic Acid; Glycine; | 2009 |
Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care.
Topics: Antidepressive Agents, Tricyclic; Antipsychotic Agents; Anxiety Disorders; Benzodiazepines; Dose-Res | 2012 |
Investigation of cortical glutamate-glutamine and γ-aminobutyric acid in obsessive-compulsive disorder by proton magnetic resonance spectroscopy.
Topics: Adolescent; Adult; Age of Onset; Brain Chemistry; Cerebral Cortex; Data Interpretation, Statistical; | 2012 |
Effects of mood stabilizers on marble-burying behavior in mice: involvement of GABAergic system.
Topics: Animals; Antipsychotic Agents; Baclofen; Behavior, Animal; Bicuculline; Carbamazepine; Dose-Response | 2013 |
Rebound psychiatric and physical symptoms after gabapentin discontinuation.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Fluoxetin | 1998 |
A case report of reduction in alcohol craving and protection against alcohol withdrawal by gabapentin.
Topics: Acetates; Adult; Alcohol Drinking; Alcoholism; Amines; Animals; Anticonvulsants; Comorbidity; Cycloh | 1999 |
[The mechanism of alteration of monoamine metabolism in brain regions in marble burying behavior-isolated housing mice and effect of oren-gedoku-to on this alteration].
Topics: Animals; Biogenic Monoamines; Brain; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; gamma- | 2000 |
[Complex treatment of obsessive states of different etiology].
Topics: Adult; Aged; Amitriptyline; Antidepressive Agents; Benactyzine; Diazepam; Drug Therapy, Combination; | 1978 |